CBD Outperforms THC for Chronic Pain in Older Adults, Major 2026 Study Finds

The Study: Design and Methodology

The research compared two carefully matched groups of 484 patients each — 968 participants total — all aged 65 and older with chronic pain conditions that had proven resistant to conventional treatments.

One group received CBD-dominant full-spectrum cannabis extracts. The other received pure THC in the form of dronabinol, a synthetic THC medication that has been FDA-approved since 1985.

Study Duration and Measures

Both groups were followed for a minimum of 24 weeks, making this one of the longest controlled comparisons of CBD and THC formulations in elderly populations. Researchers tracked multiple outcome measures including pain intensity, functional improvement, sleep quality, medication reduction, and adverse events.

The study's strength lies in its real-world clinical setting. Rather than a laboratory environment, participants were treated through actual medical cannabis programs, reflecting the conditions under which most patients access cannabis-based medicines.

Key Findings: CBD Wins Across the Board

The results were striking. CBD-dominant full-spectrum extracts outperformed pure THC across every major category measured by the researchers.

Pain Reduction

Patients in the CBD group reported an average 47% reduction in pain intensity scores over the 24-week period, compared to 31% in the THC-only group. While both results represent clinically meaningful improvements, the 16-percentage-point gap was statistically significant and exceeded what researchers expected.

Functional Improvement

CBD-group patients were more likely to report increased daily activity levels, improved mobility, and reduced reliance on assistive devices. Researchers attributed this partly to the lower incidence of cognitive side effects — a critical consideration for older adults already at elevated risk for falls, confusion, and medication interactions.

Sleep Quality

Sleep quality improved in both groups, but CBD-dominant patients reported more consistent improvements and fewer disruptions. This aligns with a growing body of research suggesting that CBD's effects on the endocannabinoid system promote more natural sleep architecture compared to THC, which can induce sedation but may suppress REM sleep.

Adverse Events

Perhaps most significantly, the CBD group experienced roughly 60% fewer adverse events than the THC group. Common side effects of pure THC in elderly patients — including dizziness, disorientation, increased heart rate, and anxiety — were substantially reduced in patients receiving CBD-dominant formulations.

Why Full-Spectrum Matters

A critical detail that sets this study apart is its use of full-spectrum CBD-dominant extracts rather than CBD isolate. Full-spectrum products contain the complete range of cannabinoids, terpenes, and flavonoids naturally present in the cannabis plant, including small amounts of THC.

The 20:1 Ratio

The CBD-dominant extracts used in the study typically contained a CBD-to-THC ratio of approximately 20:1. Patients still received some THC but in amounts low enough to minimize psychoactive effects while potentially contributing to pain relief through the entourage mechanism.

This distinction matters because it demonstrates that trace amounts of THC — when combined with CBD and other plant compounds — may enhance therapeutic outcomes without producing the cognitive side effects associated with higher THC doses.

Implications for Opioid Reduction

One of the study's secondary findings carries enormous public health implications.

The Numbers

Patients in the CBD group were 34% more likely to reduce their opioid dosage during the study period compared to the THC group. Among all participants who were taking opioids at baseline, 41% achieved a clinically meaningful reduction in opioid use.

The Opioid Crisis Context

This finding arrives against a backdrop of continued opioid-related mortality in the United States. According to the CDC, approximately 75,000 Americans died from opioid overdoses in 2025. Older adults are disproportionately affected by prescription opioid dependence, as chronic pain conditions become more prevalent with age and long-term opioid use carries escalating risks.

Population-Level Evidence

Previous research has consistently shown an association between cannabis access and reduced opioid use at the population level. States with legal medical cannabis programs have documented lower opioid prescription rates and fewer opioid-related hospitalizations.

This new study adds individual-level clinical evidence to that population-level data, specifically demonstrating that CBD-dominant formulations may be the most effective cannabis-based approach for opioid reduction.

What This Means for Patients

For older adults considering cannabis for pain management, the study offers several practical insights.

Practical Guidance

• Formulation matters. Patients who can access CBD-dominant full-spectrum products may experience better outcomes than those using THC-only medications
• Patience is important. Many participants did not reach peak benefit until 8-12 weeks into treatment
• Start low, go slow. This remains the standard clinical advice, particularly for seniors who may be more sensitive to cannabis compounds

Barriers That Remain

Significant obstacles persist. Medicare does not cover cannabis-based medicines, and many older adults live on fixed incomes that make out-of-pocket cannabis costs prohibitive.

In states without medical cannabis programs — or where programs have limited product availability — accessing specifically formulated CBD-dominant extracts can be challenging.

The study's authors called for expanded insurance coverage for medical cannabis and urged state regulators to ensure that CBD-dominant products are widely available through licensed dispensaries, not just high-THC products that dominate recreational markets.

The Growing Senior Cannabis Market

This research arrives amid a dramatic demographic shift in cannabis use. Americans aged 65 and older represent the fastest-growing segment of cannabis consumers in the country.

According to a 2025 analysis from New Frontier Data, cannabis use among seniors has increased over 300% in the past decade, driven primarily by medical applications for pain, insomnia, and anxiety.

The stigma that once prevented older Americans from considering cannabis is rapidly eroding. A 2026 AARP survey found that 61% of adults over 50 now view medical cannabis favorably, and 22% reported having used cannabis in some form within the past year.

As the baby boomer generation ages and chronic pain becomes an increasingly pressing public health challenge, studies like this one may prove pivotal in shaping clinical guidelines, insurance policies, and product development priorities across the cannabis industry.